

The Latest in Lung: A Lung and Thoracic Virtual Presentation

**1.5 AMA PRA Category
1 Credit(s)TM**

November 19, 2020

Noon - 1:30 p.m.

Virtual Meeting via Zoom

Feature Presentation: *Clinical Considerations in the Care of Patients and Lung Cancer*

AGENDA

Noon - 12:05 p.m.

**Opening remarks and
introductions**

E. Shakespeare, MD

12:05 - 12:20 p.m.

**Smoking Cessation Review and
Lung Cancer Screening Eligibility**

E. Shakespeare, MD

12:20 - 12:35 p.m.

**Low Dose CT for Lung Cancer
Screening: Case Based Approach
to Understanding and Applying
Lung-RADS**

J. Hochhold, MD

12:35 - 12:50 p.m.

**The Evaluation of Lung Cancer
Risk and Genomics Sequencing
Classification**

N. Maouelainin, DO, MBA

12:50 - 1:05 p.m.

**Medical Oncology Treatment
Options for Lung Cancer**

M. Morginstin, DO

1:05 - 1:25 p.m.

Question and Answer Period

E. Shakespeare, MD / ALL

1:25 - 1:30 p.m.

Closing Remarks

E. Shakespeare, MD

FACULTY

Eric Shakespeare, MD
Pulmonologist

John Hochhold, MD
Radiologist

Nina Maouelainin, DO, MBA
Interventional Pulmonologist

Mark Morginstin, DO
*Medical Oncologist and
Hematologist*

**REGISTER ONLINE
AT [EINSTEIN.EDU/
LUNG-CME](https://einstein.edu/lung-cme)**



**FOR QUESTIONS,
PLEASE CALL
484-622-7444**

Continuing Medical Education for Physicians

Accreditation Statement:

Albert Einstein Healthcare Network is accredited by the Pennsylvania Medical Society to provide Continuing Medical Education for physicians.

Updated Credit Designation Statement:

Albert Einstein Healthcare Network designates this Live Activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the educational activity.

Classifications:

This activity includes 1.5 hours of Patient Safety and Risk Management education.

Conflict of Interest Statement:

Faculty and all others who have the ability to control the content of continuing medical education activities sponsored by Einstein Healthcare Network are expected to disclose to the audience whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s). The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Statement of Support:

This activity is not commercially supported.

Target Audience:

This activity is designed for primary care oncologists, medical oncologists, radiation oncologists, pulmonologists, thoracic surgeons, respiratory therapists, internal medicine physicians, nurse practitioners, physician assistants, nurses, residents and fellows involved in the care of patients with lung disorders and/or chest diseases.

Statement of Need:

Lung cancer remains the deadliest cancer in the world, however, it can be cured if detected early. Significant progress has been made recently in early detection and diagnosis, non-surgical staging and more personalized treatment options, according to stage and specific targeted therapy.

The Latest in Lung: A Lung and Thoracic Symposium sponsored by the Lung and Thoracic Program at Einstein Medical Center Montgomery will bring the latest updates to clinicians in Montgomery County, providing attendees with the newest oncology. Experts in the field will discuss updates on lung cancer screening, including updates made by CMS; advanced bronchoscopy, including endobronchial ultrasound; robotic surgery for lung cancer; personalized radiation and chemotherapy; as well as common pulmonary diseases, such as asthma and COPD. These expert sessions will be complimented by a course in tobacco cessation counseling and nicotine replacement therapy.

Series Learning Objectives:

- Quantify the effect of physician advice on smoking cessation efforts and name two modes of smoking cessation.
- Differentiate pulmonary nodules based on density and morphology and recognize the benefits and limitations of low dose CT technique.
- Identify different genomic sequencing tools and discuss the benefits of genomic sequencing for lung cancer.
- Describe the rationale behind adjuvant and neoadjuvant treatment for lung cancer and summarize the rationale for first line TKI/ immunotherapy in the metastatic lung cancer setting.

Event Disclosures:

Speakers:

- **John Hochhold, MD** has no relevant financial relationships to report in the last 12 months with a commercial interest.
- **Nina Maouelainin, DO** has no relevant financial relationships to report in the last 12 months with a commercial interest.
- **Mark Morginstin, DO** has no relevant financial relationships to report in the last 12 months with a commercial interest.
- **Eric Shakespeare, MD** has no relevant financial relationships to report in the last 12 months with a commercial interest.

Planners and other Administrative Support:

- **Mary Galetti, RN** has no relevant financial relationships to report in the last 12 months with a commercial interest.
- **Marc Schaller, MBA** has no relevant financial relationships to report in the last 12 months with a commercial interest.
- **Eric Shakespeare, MD** has no relevant financial relationships to report in the last 12 months with a commercial interest.
- **Pat Modafferi** has no relevant financial relationships to report in the last 12 months with a commercial interest.
- **Cheryl Cleveland-Stewart** has no relevant financial relationships to report in the last 12 months with a commercial interest.